Displaying 58 (all) recruiting clinical trials.
-
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
The purpose of the study is to determine the safety and efficacy of INCMGA00012 monotherapy or in combination with other immunotherapy or targeted agents (combinations ...Phase
Interventional
-
A RANDOMIZED PHASE II/III OPEN-LABEL STUDY OF IPILIMUMAB AND NIVOLUMAB VERSUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MGMT (TUMOR O-6-METHYLGUANINE DNA METHYLTRANSFERASE) UNMETHYLATED GLIOBLASTOMA
The purpose of the study is to determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs progression-free survival (PFS) versus adding temozolomide to radiotherapy ...Phase
Interventional
-
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
The purpose of the study is to determine the safety and efficacy of Adavosertib (AZD1775) for patients who have locally advanced, or metastatic solid tumor ...Phase
Interventional
-
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that ...Phase
Interventional
-
GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients
The purpose of the trial is to assess the safety and efficacy of the Gene Mediated Cytotoxic Immunotherapy (GMCI) added to standard of care immune ...Phase
Interventional
-
DAY101-001/PNOC026/FIREFLY-1: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Altered Recurrent or Progressive Low-Grade Glioma
The purpose of the study is to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with ...Phase
Interventional
-
AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged >/=1 to
The purpose of the study is to investigates how well nivolumab when given together with blinatumomab work compared to blinatumomab alone in treating patients with ...Phase
Interventional
-
A Phase 2 Trial of the Combination of Polatuzumab Vedotin Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
The purpose of the study is to evaluate the activity of a novel triplet combination of rituximab and hyaluronidase human, polatuzumab vedotin, and venetoclax for ...Phase
Interventional
